Top Stories
The funding follows FDA clearance for its implantable monitor ECG analyser, which Implicity says can cut false-positive episodes by up to 76%.
Brainomix's 360 E-lung software found that patients treated with taladegib had "significant positive differences" in lung volume, overall interstitial lung disease burden and total fibrosis extent.
The series C round comes just months after the healthcare automation startup raised more than $160 million.
In separate studies, CART produced usable readings for about 80% of a 24-hour period in atrial fibrillation patients and closely matched a standard 24-hour blood pressure monitor in severe heart failure.
Rentosertib, now in Phase III trials for idiopathic pulmonary fibrosis, showed age-reversal signals that appeared partly independent of improvements in lung function, pointing to potential anti-aging effects beyond its respiratory benefits.
Conference News
A new initiative to connect and empower early-career pathologists across EuropeSakura Finetek Europe today announced the launch of the Sakura Pathology Network (SPN), a new European network bringing t...
Research highlights the significance of genomic and epigenomic profiling approaches to characterize lung tumors, identify biomarkers, and support risk stratificationReal-world studies examine the comp...
This strong commercial momentum is fueled by the global expansion of its clinical-grade Breast AI Suite, now completed with the release of Ibex Lymph Node* spanning biopsies, excisions, IHC, and metas...
Trialbee continues to bring fresh innovation to clinical trials with its Honey Platform™, demonstrating how AI is reshaping patient recruitment – and where it goes from hereMALMO, Sweden & WILMINGTON,...
VR represents a low-cost, scalable intervention that improves patient experience while supporting efficient use of imaging resourcesContact: Katie Glenn, kglenn@acc.org ORLANDO (Sep 08, 2026) - Patien...
